TSC2 and hamartoma: In the tumor model of mice with heterozygous mutations in TSC2 (Tsc2+/- ) there was no reduction in tumor size after metformin treatment compared with those treated with rapamycin, suggesting limited therapeutic benefits of metformin in treating hamartomas (Auricchio et al., 2012).